Name: Ms. BELA MUKHERJEE Client Name: KOL-14-02 Barcode No.
: 5980614
PATIENT DETAILS
REPORT DETAILS
CLIENT DETAILS
Age/Gender: 81 Y/Female Client Address: MOULALI Collected on: 12/Jul/2025 03:34PM
Lab No: 012507120902
Referred By: Dr. BUDDHADEB BASU Reported on: 12/Jul/2025 05:21PM
Ref Lab/Hospital.: Self @1
Test Name Result Unit Biological Ref.Interval Method
DIABETES SCREENING PLUS
Lipid Profile
*Cholesterol Total (CHOL) 135 mg/dL Desirable: <200 CHOD Enzymetic Colorimetric
Borderline High: 200-239
High: >=240
*Cholestrol (HDL) 54 mg/dL High Risk: <40 Homogeneous Enzymatic
Moderate Risk: 40 - 60 Colorimetric
No Risk: >60
Cholesterol NON HDL 81.00 Calculated
*Triglycerides (TRIG) 105 mg/dL Normal: <150 GPO - PAP
BorderLine: 150-199
High: 200-499
Very High: >=500
Cholesterol LDL 60 mg/dL Homogeneous Enzymetic
Colorimetric
Cholesterol (VLDL) 21 mg/dL < 30 Calculated
*CHOL Total to CHOL HDL Ratio 2.50 Ratio Low Risk: 3.3 - 4.4 Calculated
Average Risk: 4.5 - 7.0
Moderate Risk: 7.1 - 11.0
High Risk: >=500
CHOL LDL to CHOL HDL Ratio 1.1 Ratio Desirable/Low Risk: 0.5 - 3.0 Calculated
Borderline/Moderate Risk: 3.1 - 6.0
High Risk: > 6.0
CHOL Total to CHOL LDL Ratio 2.2 Ratio Calculated
*TRIG to CHOL HDL Ratio 2 Calculated
ASCVD Risk Estimator -NA- % 10-year risk for ASCVD is categorized Calculated
as:
Low-risk (<5%)
Borderline risk (5% to 7.4%)
Intermediate risk (7.5% to 19.9%)
High risk (≥20%)
Sample Type:Serum
Page 1 of 5
Name: Ms. BELA MUKHERJEE Client Name: KOL-14-02 Barcode No.: 5980614
PATIENT DETAILS
REPORT DETAILS
CLIENT DETAILS
Age/Gender: 81 Y/Female Client Address: MOULALI Collected on: 12/Jul/2025 03:34PM
Lab No: 012507120902
Referred By: Dr. BUDDHADEB BASU Reported on: 12/Jul/2025 05:17PM
Ref Lab/Hospital.: Self @1
Test Name Result Unit Biological Ref.Interval Method
COMPLETE BLOOD COUNT (CBC)
*Haemoglobin (HGB) 14.8 gm/dL 10.2 - 13.0 Colorimetric Method
*Total Red Blood Count (RBC) 4.82 m/cumm 4.00 - 5.40 Electrical Impedance
*Haematocrit (PCV) 46.8 % 40 - 54 Calculated
*Mean Corpuscular Volume (MCV) 97.1 fL 80 - 94 Calculated
*Mean Corpuscular Haemoglobin 30.7 pg 26 - 32 Calculated
(MCH)
*Mean Corpuscular Haemoglobin 31.6 g/dL 32 - 36 Calculated
Concentration (MCHC)
RDW-CV 16.2 % 11.5-14.5 Dc Detection Method
(Calculated)
*Platelet Count (PLT) 175.00 thou/cumm 150.00 - 400.00 Electrical Impedance &
Microscopy
*Total Leucocyte Count (WBC) 5.9 thou/cu.mm 4.0 - 11.5 Laser-based Flow Cytometry
Differential Leucocyte Count (DC)
*Neutrophils Percentage Count (NE%) 70 % 50 - 70 Flowcytometry/Microscopy
*Neutrophil Absolute Count (NEU) 4,130 /cu.mm 2000 - 7000 Flowcytometry/Microscopy
*Lymphocytes Percentage Count 25 % 18 - 42 Flowcytometry/Microscopy
(LY%)
*Lymphocyte Absolute Count (LYM) 1,475 /cu.mm 1800 - 4200 Flowcytometry/Microscopy
*Monocytes Percentage Count (MO%) 03 % 2 - 11 Flowcytometry/Microscopy
*Monocyte Absolute Count (MO) 177 /cu.mm 200 - 1000 Flowcytometry/ Microscopy
*Eosinophil Percentage Count (ESO%) 02 % 1-3 Flowcytometry/Microscopy
*Eosinophil Absolute Count (EOS) 118 /cmm 20 - 500 Flowcytometry/Microscopy
*Basophils Percentage Count (BAS%) 00 % 0-2 Electrical
Impedance/Microscopy
*Basophils Absolute Count (BAS) 0.00 x 10^3 0.00-0.00 Electrical
cells/uL Impedance/Microscopy
Sample Type:Whole Blood EDTA
RBC: NORMOCYTIC NORMOCHROMIC.
Page 2 of 5
Name: Ms. BELA MUKHERJEE Client Name: KOL-14-02 Barcode No.: 5980614
PATIENT DETAILS
REPORT DETAILS
CLIENT DETAILS
Age/Gender: 81 Y/Female Client Address: MOULALI Collected on: 12/Jul/2025 03:34PM
Lab No: 012507120902
Referred By: Dr. BUDDHADEB BASU Reported on: 12/Jul/2025 05:22PM
Ref Lab/Hospital.: Self @1
Test Name Result Unit Biological Ref.Interval Method
Vitamin D Total 25 Hydroxy (Calcidiol) 9.30 ng/mL Deficiency < 20.00 ECLIA
Insufficiency 21.00 - 30.00
sufficiency 31.00 - 100.00
Toxicity > 100.00
Sample Type:Serum
Interpretation:
Vit D is the fat soluble vitamin and exists in two main forms as cholecalciferol ( Vit D3) which is synthesized in skin from 7 dehydrocholesterol in
response to sunlight exposure and Ergocalciferol ( Vit D2) present mainly in dietery sources . Both cholecalciferol & Ergocalciferol are converted to
25(OH) vitamin D in liver.
Testing for 25(OH) vitamin D is recommended as it is the best indicator of vitamin D nutritional status as obtained from sunlight exposure & dietary
intake. For diagnosis of Vitamin D deficiency it is recommended to have clinical correlation with serum 25(OH) vitamin D, serum calcium, serum
PTH and serum alkaline phosphate,
During monitoring of oral vitamin D therapy- suggested testing of serum 25(OH)vitamin D supplement and time to achieve sufficient vitamin D
levels show significant seasonal (especially winter) and individual variability depending on age, body fat, sun exposure, physical activity, genetic
factor associated renal or liver disease , malabsorption syndromes and calcium or magnesium deficiency influencing the vitamin D metabolism..
Vitamin D toxicity is known but very rare.
Page 3 of 5
Name: Ms. BELA MUKHERJEE Client Name: KOL-14-02 Barcode No.: 5980614
PATIENT DETAILS
REPORT DETAILS
CLIENT DETAILS
Age/Gender: 81 Y/Female Client Address: MOULALI Collected on: 12/Jul/2025 03:34PM
Lab No: 012507120902
Referred By: Dr. BUDDHADEB BASU Reported on: 12/Jul/2025 05:22PM
Ref Lab/Hospital.: Self @1
Test Name Result Unit Biological Ref.Interval Method
Thyroid Panel
*Total Triiodothyronine (T3) 1.28 ng/mL Hypothyroid < 0.80 ECLIA
Euthyroid 0.80 - 2.00
Hyperthyroid > 2.00
*Total Thyroxine (T4) 7.40 µg/dL Hypothyroid < 5.10 ECLIA
Euthyroid 5.10 - 14.10
Hyperthyroid > 14.10
*TSH (3rd Generation) 1.960 µIU/mL Hyperthyroid < 0.270 ECLIA
Euthyroid 0.270 - 4.200
Hypothyroid > 4.200
Sample Type:Serum
Interpretation :
Thyroid Stimulating Hormone is a glycoprotein with two – covalently bound subunits.The alpha subunit is similar to those of follicle stimulating hormone (FSH), human
chorionic gonadotrophin (hCG) and Luteinizing Hormone (LH).The beta submit of TSH is unique, which results in the specific biochemical and immunological properties of this
hormone.TSH is synthesized and secreted by the anterior pituitary in response to a negative feedback mechanism involving concentrations of FT3 (Free T3) and FT4 (Free
T4).Additionally, the hypothalamic tripeptide, thyrotropoin – releasing hormone (TSH), directly stimulates TSH production.TSH interacts with specific cell receptors on the
thyroid cell surface and exerts two main actions.The first action is to stimulate cell reproduction and hypertrophy.Secondly,TSH stimulates the thyroid gland to synthesize and
secrete T3 and T4 .In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism TSH levels are low.
Below mentioned are the guidelines for pregnent woman related reference ranges of TSH recomemded by Americal Thyroid Association:
Pregnancy uIU/mL
First Trimester 0.600 - 3.400
Second Trimester 0.370 - 3.600
Third Trimester 0.380 - 4.040
Page 4 of 5
Name: Ms. BELA MUKHERJEE Client Name: KOL-14-02 Barcode No.: 5980614
PATIENT DETAILS
REPORT DETAILS
CLIENT DETAILS
Age/Gender: 81 Y/Female Client Address: MOULALI Collected on: 12/Jul/2025 03:34PM
Lab No: 012507120902
Referred By: Dr. BUDDHADEB BASU Reported on: 12/Jul/2025 05:21PM
Ref Lab/Hospital.: Self @1
Test Name Result Unit Biological Ref.Interval Method
*Fasting Blood Glucose (FBS) 124 mg/dL 70 - 110 Hexokinase
Sample Type:Fluoride Plasma
Interpretation :
*A fasting plasma glucose level below 110 mg/dL is considered normal.
*A fasting plasma glucose level between 110-126 mg/dL is considered as glucose intolerant or pre diabetic. A fasting and post-prandial blood sugar test (after consumption of 75 gm of glucose) is recommended for all
such patients.
*A fasting plasma glucose level of above 126 mg/dL is highly suggestive of a diabetic state. A repeat fasting test is strongly recommended for all such patients. A fasting plasma glucose level in excess of 126 mg/dL on
both the occasions is confirmatory of a diabetic state.
Blood Glucose is maintained by a complex interplay of hormones. In diabetes (Both Type I & Type II), various genetic, metabolic and environmental factors lead to progressive loss of Beta Cell Mass or insulin sensitivity,
manifesting as hyperglycemia. Stressful events (eg. Infection, illness, surgery, trauma) too may worsen glycemic control. Any condition leading to deterioration of glycemic control requires more frequent monitoring of
blood glucose.
Reference :
CLASSIFICATION AND DIAGNOSIS OF DIABETES: STANDARD OF MEDICAL CARE IN DIABETES – 2019. Diabetes Care 2019.
*Postprandial Glucose (PP) 200 mg/dL 70 - 140 Hexokinase
Sample Type:Fluoride Plasma
Interpretation :
Blood Glucose is maintained by a complex interplay of hormones. In diabetes (Both Type I & Type II), various genetic, metabolic and environmental factors lead to progressive loss of Beta Cell Mass or insulin sensitivity,
manifesting as hyperglycemia. Stressful events (eg. Infection, illness, surgery, trauma) too may worsen glycemic control. Any condition leading to deterioration of glycemic control requires more frequent monitoring of
blood glucose.
Reference:
CLASSIFICATION AND DIAGNOSIS OF DIABETES: STANDARD OF MEDICAL CARE IN DIABETES-2019. Diabetes Care 2019
*Creatinine (CREA) 0.70 mg/dL 0.50 - 0.90 Jaffe Kinetic Colorimetric
Sample Type:Serum
Test has been performed on COBASPRO_2
For test performed on specimens received or collected from non-HPDPL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the
point generation of the said specimen by the sender. HPDPL will be responsible only for the analytical part of test carried out. All other responsibility will be of referring Laboratory.
*** End Of Report ***
Page 5 of 5
